Ethris and EIB Sign €30M Financing for Antiviral
Munich, Germany, September 10, 2026 Ethris GmbH and the European Investment Bank (EIB) have signed a €30 million financing...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Munich, Germany, September 10, 2026 Ethris GmbH and the European Investment Bank (EIB) have signed a €30 million financing...
San Diego, California, and Suzhou, China, September 10, 2026 Adagene Inc. and Third Arc Bio, Inc. have announced the...
Burlington, Massachusetts, U.S., September 10, 2026 Consano Bio, Inc. has announced the publication of peer-reviewed nonclinical research evaluating C-1101,...
BURLINGTON, Mass., August 18, 2026 Consano Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
NEW YORK, May 27, 2026 Yuka, the independent food and cosmetic scoring application used by more than 85 million...
BURLINGTON, Massachusetts, May 26, 2026 Consano Bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for painful...
